• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

New Delhi, March 11

Dabur Pharma Ltd has announced that it has received approvals for Irinotecan Hydrochloride Injection in Italy and Denmark. The company had successfully launched the generic version of the drug in the US recently. It also has approval for the drug in the UK. Speaking on the occasion, the Chief Executive Officer of Dabur Pharma Ltd, Mr Ajay Kumar Vij, said “We are extremely pleased to receive these approvals for Irinotecan across Europe. This bears a testimony to the s trong foundation we are laying towards becoming one of the leading oncology players across the globe. Irinotecan Hydrochloride Injection is the generic version of Pfizer’s Camptosar. It is indicated as a component of first-line therapy for colon cancer.” —

Our Bureau

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Electrotherm launches corrosion resistant steel bars

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line